Citadel Advisors’s SOPHiA GENETICS SOPH Stock Holding History

Citadel Advisors’s Portfolio SOPH Stock Details SOPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$858K	Buy	148,700 +119,500	+409%	+$606K	﹤0.01%	8594
2026 Q1	$145K	Buy	+29,200	New	+$142K	﹤0.01%	11717
2025 Q2	–	Sell	-500	Closed	-$1.66K	–	14896
2025 Q1	$1.66K	Sell	500 -500	-50%	-$1.76K	﹤0.01%	14115
2024 Q4	$3.12K	Sell	1,000 -4,900	-83%	-$16.7K	﹤0.01%	14024
2024 Q3	$21.4K	Buy	+5,900	New	+$24K	﹤0.01%	12726
2024 Q1	–	Sell	-100	Closed	-$471	–	15381
2023 Q4	$471	Hold	100	–	–	﹤0.01%	14024
2023 Q3	$255	Hold	100	–	–	﹤0.01%	14109
2023 Q2	$448	Buy	+100	New	+$452	﹤0.01%	14118

Other funds holding SOPH

GIM

Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

ACM

AKRE Capital Management Middleburg, Virginia $5.12B AUM 19.08% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return

Citadel Advisors's SOPH Position: Q2 2026 in Review

Citadel Advisors opened a new position in SOPHiA GENETICS (SOPH) in Q2 2026: 38,497 shares worth $222K. The stake represents ﹤0.01% of the portfolio and ranks #11822 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in SOPH as recently as Q3 2025.

Citadel Advisors first reported a position in SOPH in Q4 2021 and has held it in 13 quarters since. The position peaked at $334K in Q1 2023. 71 funds tracked by Wall St. Rank hold SOPH as of Q2 2026.

Citadel Advisors held 38,497 shares of SOPHiA GENETICS worth $222K as of Q2 2026.
SOPHiA GENETICS was a new Citadel Advisors position in Q2 2026.
SOPHiA GENETICS made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11822 holding.
Citadel Advisors first reported a position in SOPHiA GENETICS in Q4 2021 and has held it in 13 quarters since.
Citadel Advisors's SOPHiA GENETICS position peaked at $334K in Q1 2023.
71 funds tracked by Wall St. Rank held SOPHiA GENETICS as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.